Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL0020 in Transformed Small Cell Lung Cancer
NCT07414927Phase 2Not yet recruiting
- Sponsor
- Shanghai Best-Link Bioscience
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BL0020 in small cell lung cancer (SCLC), sponsored by Shanghai Best-Link Bioscience. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
BL0020
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07414927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07414927.